PRISM Trial Update Presented at RWC

4D-150 is designed for single, low-dose intravitreal delivery for transgene expression from the retina.

Retinal Physician May 9, 2025

Clinical Report: PRISM Trial Update Presented at RWC

Overview

The PRISM trial update highlights the efficacy and safety of 4D-150, a novel gene therapy for wet AMD, showing promising results with significant reductions in injection frequency and stable visual acuity. The trial indicates that 80% of recently diagnosed patients were injection-free at 52 weeks.

Background

Wet age-related macular degeneration (AMD) is a leading cause of vision loss, and current treatments primarily involve frequent intravitreal injections of anti-VEGF agents. The development of gene therapies like 4D-150 aims to reduce treatment burden while maintaining efficacy. Understanding the outcomes of the PRISM trial is crucial for advancing treatment options in this patient population.

Data Highlights

{'corrected_injection_free_percentage': '57% overall, 80% for recently diagnosed patients'}

Key Findings

{'clarified_injection_free_percentage': '57% overall, 80% for recently diagnosed patients'}

Clinical Implications

The results from the PRISM trial suggest that 4D-150 could significantly reduce the treatment burden for patients with wet AMD, potentially allowing for longer intervals between treatments. Clinicians should consider the implications of these findings when discussing treatment options with patients.

Conclusion

The PRISM trial update presents promising data for 4D-150 as a viable treatment option for wet AMD, with ongoing phase 3 trials expected to further validate these findings.

PentaVision

Retinal Physician